Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

Survodutide administered weekly leads to approximately 8-10% weight loss in adults with obesity and type 2 diabetes, outperforming placebo in a phase 3 trial.

• Why it matters: Effective weight management is crucial for controlling type 2 diabetes, yet optimal therapies are limited. This study addresses the need for potent, once-weekly treatments that can significantly reduce weight and improve metabolic outcomes.
• What they did: The trial involved 752 adults with a BMI of 27 or higher, randomly assigned to receive 3.6 mg or 6.0 mg of survodutide or placebo, with primary endpoints measuring percent weight change and at least 5% weight loss at 76 weeks.
• The result: Participants on survodutide experienced substantial weight loss (-8.2% and -9.8%) and improved glycemic control, with over 57% achieving at least 5% weight reduction, supporting survodutide's potential as an effective obesity and diabetes therapy.